# Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

Source: https://onco.cc/trials/nct01137682/  
OnCo record `nct01137682` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pasireotide in Pituitary tumours, run by Novartis Pharmaceuticals, completed.

## Summary

Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly is a phase 3 interventional study registered as NCT01137682 by Novartis Pharmaceuticals, with 198 participants recorded, started 2010-07-19 and reaching its primary completion in 2013-01-22. Interventions recorded: Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg. Conditions recorded: Acromegaly.

Linked to the drug Pasireotide because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01137682
- Phase: 3
- Setting: A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 198

## Sources

- ClinicalTrials.gov NCT01137682: https://clinicaltrials.gov/study/NCT01137682

## Connected records

- cancers: [Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma](https://onco.cc/cancers/pituitary-tumours/)
- drugs: [Pasireotide](https://onco.cc/drugs/pasireotide/)

---
JSON: https://onco.cc/api/v1/entities/nct01137682.json